A-Seeds Australia

A-SEEDS is a clinical-stage biotechnology company specializing in regenerative medicine, with a focus on mesenchymal stem cell (MSC) therapies. The company's core technology, the A-SEEDS (Advanced Seeds) platform, enables the selection and expansion of high-quality MSCs to ensure therapeutic consistency and potency. Its lead program, AS-01, is being developed for the treatment of acute Graft-versus-Host Disease (GvHD), a life-threatening condition following hematopoietic stem cell transplantation. A-SEEDS Australia serves as the company's clinical development arm in the Asia-Pacific region, leveraging Australia's robust clinical trial infrastructure. The company is a spin-off from research conducted at the University of Tokyo and Kyoto University.